Assessment of adherence and asthma medication ratio (AMR) for a once-daily and twice-daily inhaled corticosteroid/long acting beta agonist (ICS/LABA) for asthma
ConclusionsAdherence and treatment persistence were low in both cohorts, however, patients initiating once-daily FF/VI were more likely to be adherent, have an AMR ≥0.5, and were less likely to discontinue therapy compared with patients initiating twice-daily BUD/F. (GSK Study HO1617302/206482)
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Cystic Fibrosis | Flonase | Medicare | Respiratory Medicine | Study | Symbicort